January 8, 2024

River Stone awarded key US patent

River Stone advancing to global commercial launch of its disruptive substance abuse API offering.

River Stone Bio

Cambridge, December 18, 2023 – River Stone Biotech Inc.(RSB), a synthetic biology business centered around a disruptive specialty API offering, today announced the issuance of a U.S. Patent covering a key family of enzymes enabling preparation of precursors to high value compounds such as buprenorphine, naloxone, naltrexone, and nalmefene. These enzymes are key to enabling a process that is higher efficiency and uses more environmentally-friendly reagents than conventional production methods. This production approach works synergistically with RSB’s proprietary chemistry methods, as described in previously granted US 11,390,628 and AU 2018268173, to generate these high value APIs.

U.S. Patent No. US 11,781,164 is entitled “Demethylation of reticuline and derivatives thereof with fungal cytochrome P450 “was granted on October 10, 2023 is expected to provide RSB with protection until 2039.

Paula Hicks, SVP of Technology and IP for RSB, said, “This newly issued U.S. patent illustrates the synergistic nature of our technology in taking the best approaches from biology and chemistry to realize the commercial potential of our life-saving APIs. The growth of our aggressive IP portfolio is core to the RSB strategy which we believe is creating significant value for both our shareholders and wider stakeholders alike”

Tim Bowser, Chief Technical Officer, River Stone, added “This issuance provides further endorsement of the company’s long term plans and is testament to the many scientists that have worked, and continue to work, on our novel approach that will soon provide customers the ability to purchase lifesaving APIs that are produced via our exciting, hybrid platform. We have already reached commercial scale with our biology process; the coming months will see the same achievement with our chemistry processes. Our regulatory activity is in sync with these production advancements which makes for a very exciting 12-month outlook.”

About River Stone Biotech Inc.

RSB is headquartered in Cambridge, MA, US with development sites in Denmark and Australia; its highly experienced management team has taken multiple projects from concept through method development and into commercial-scale production.  RSB is dedicated to providing life changing APIs and formulations via innovative production methods that blend synthetic biology and chemistry processes.

In the first instance RSB is pleased to be able to make a meaningful contribution to the important Opioid Dependence/Substance Abuse Prevention programs around the world.

River Stone works with a small number of global providers to establish a virtual cross-functional operation to enable its API offering.

River Stone Biotech Inc. Contact

Corporate contact:
Simon Ball
River Stone Biotech Inc.